Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-004889-26
    Sponsor's Protocol Code Number:EFC14837
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-07-31
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-004889-26
    A.3Full title of the trial
    A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment who have Inadequate Glycemic Control
    Estudio multicéntrico, aleatorizado, con enmascaramiento doble, de tres grupos paralelos controlados con placebo de 52 semanas de duración para evaluar la eficacia y la seguridad de sotagliflozina en pacientes con diabetes mellitus de tipo 2 e insuficiencia renal moderada con un control inadecuado de la glucemia
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Safety and Efficacy Study of Sotagliflozin on Glucose Control in Patients with Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
    Estudio de la seguridad y la eficacia de sotagliflozina en pacientes con diabetes mellitus de tipo 2 e insuficiencia renal moderada con un control inadecuado de la glucemia
    A.3.2Name or abbreviated title of the trial where available
    SOTA-CKD3
    SOTA-CKD3
    A.4.1Sponsor's protocol code numberEFC14837
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1187-8662
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorSanofi-aventis Recherche & Développement
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSanofi-aventis Recherche & Développement
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationsanofi-aventis, s.a.
    B.5.2Functional name of contact pointUnidad Estudios Clínicos
    B.5.3 Address:
    B.5.3.1Street Addressc/ Josep Pla 2, 4ª planta
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08019
    B.5.3.4CountrySpain
    B.5.4Telephone number93 485 94 00
    B.5.6E-mailes-unidadestudiosclinicos@sanofi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSotagliflozin
    D.3.2Product code SAR439954
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSOTAGLIFLOZIN
    D.3.9.1CAS number 1018899-04-1
    D.3.9.2Current sponsor codeSAR439954
    D.3.9.3Other descriptive nameLX4211, LX-4211, LP-802034
    D.3.9.4EV Substance CodeSUB179285
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Type 2 diabetes mellitus
    Chronic kidney disease stage 3
    Diabetes mellitus de tipo 2 (DMT2)
    Insuficiencia renal moderada (estadío 3)
    E.1.1.1Medical condition in easily understood language
    Type 2 diabetes mellitus
    Chronic kidney disease stage 3
    Diabetes mellitus de tipo 2 (DMT2)
    Insuficiencia renal moderada (estadío 3)
    E.1.1.2Therapeutic area Diseases [C] - Hormonal diseases [C19]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10067585
    E.1.2Term Type 2 diabetes mellitus
    E.1.2System Organ Class 10027433 - Metabolism and nutrition disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10076410
    E.1.2Term Chronic kidney disease stage 3
    E.1.2System Organ Class 100000070575
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the superiority of sotagliflozin dose 1 and 2 versus placebo on HbA1c reduction in patients with Type 2 diabetes who have inadequate glycemic control and moderate renal impairment
    Demostrar la superioridad de la sotagliflozina a una dosis de 400 mg y 200 mg frente al placebo parar reducir la hemoglobina A1c (HbA1c) en pacientes con diabetes mellitus de tipo 2 (DMT2) que tienen una insuficiencia renal moderada con un control inadecuado de la glucemia.
    E.2.2Secondary objectives of the trial
    -To assess the effects of sotagliflozin dose 1 and 2 versus placebo with respect to additional measures of glycemic control, blood pressure, and body weight
    -To evaluate the safety of sotagliflozin dose 1 and dose 2 versus placebo
    Evaluar los efectos de la sotagliflozina a una dosis de 400 mg y 200 mg frente a los del placebo, en función de los datos obtenidos de la glucemia plasmática, la tensión arterial sistólica y peso corporal.
    Evaluar la seguridad de la sotagliflozina a dosis de 400 mg y 200 mg frente a placebo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -Patients with T2D (drug-naïve or on antidiabetic therapy) and documented moderate renal insufficiency defined by an eGFR (based on the 4 variable Modification of Diet in Renal Disease [MDRD] equation) of ≥30 and <60 mL/min/1.73 m2 (CKD 3A, 3B).
    -Patient has given written informed consent to participate in the study in accordance with local regulations.
    - Pacientes con DMT2 (sin tratamiento previo o con tratamiento antidiabético) e insuficiencia renal moderada documentada, que se define por una TFGe (basada en la ecuación de MDRD de 4 variables) de ≥30 y <60 ml/min/1,73 m2 (NC 3A, 3B).
    - El paciente que ha otorgado consentimiento informado por escrito para participar en el estudio de conformidad con las normativas locales.
    E.4Principal exclusion criteria
    -Hemoglobin A1c (HbA1c) of <7.0% or >11.0%.
    -Type 1 diabetes.
    -Women who could become pregnant.
    -Treatment with an SGLT2 inhbitor (canagliflozin, dapagliflozin, empagliflozin) during the last 12 months.
    -Uncontrolled high blood pressure.
    -Severe anemia, severe cardiovascular problems, such as heart failure, active cancer, or other conditions that the Investigator believes will result in a short life expectancy.
    - Valores de HbA1c <7,0 % o HbA1c >11 %
    - Diabetes mellitus de tipo 1.
    - Mujeres fértiles que no estén dispuestas a utilizar métodos anticonceptivos de gran eficacia o que no deseen o no puedan someterse a pruebas de embarazo.
    - Uso de un inhibidor selectivo de SGLT2 (p.ej., canagliflozina, dapagliflozina o empagliflozina) en los 12 meses previos al ensayo.
    - Tensión arterial alta no controlada.
    - Pacientes con anemia grave, enfermedad grave de tipo cardiovascular (p.ej. la insuficiencia cardíaca congestiva de clase IV), cáncer activo o pacientes con una esperanza de vida corta en opinión del investigador.
    E.5 End points
    E.5.1Primary end point(s)
    Change in HbA1c for dose 1 and dose 2
    Cambio de la HbA1c (%) a una dosis de 400 mg y a una dosis de 200 mg
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline to Week 26
    Desde el inicio del estudio hasta la semana 26
    E.5.2Secondary end point(s)
    1. Change in Fasting Plasma Glucose (FPG)
    2. Change in Systolic Blood Pressure (SBP) for patients with
    SBP ≥130 mmHg
    3. Change in Systolic Blood Pressure (SBP)
    4. Change in body weight
    5. Change in urinary albumin-to-creatinine ratio (UACR)
    6. Patients with HbA1c <6.5%
    7. Patients with HbA1c <7.0%
    8. Patients with adverse events
    1. Cambio en la glucemia plasmática en ayunas (GPA)
    2. Cambio de la tensión arterial sistólica (TAS) para los pacientes con una TAS basal de ≥130 mmHg
    3. Cambio de la tensión arterial sistólica TAS.
    4. Cambio en el peso corporal
    5. Cambio porcentual del cociente albúmina/creatinina (CAC)
    6. Pacientes con HbA1c inferior a 6.5%
    7. Pacientes con HbA1c inferior a 7.0%
    8. Pacientes con acontecimientos adversos
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Change in Fasting Plasma Glucose (FPG) : Baseline to Week 26
    2. Change in Systolic Blood Pressure (SBP) for patients with
    SBP ≥130 mmHg : Baseline to Week 12
    3. Change in Systolic Blood Pressure (SBP) : Baseline to Week 12
    4. Change in body weight : Baseline to Week 26
    5. Change in urinary albumin-to-creatinine ratio (UACR) : Baseline to Week 26
    6. Patients with HbA1c <6.5% : Week 26
    7. Patients with HbA1c <7.0% : Week 26
    8. Patients with adverse events : Week 26
    1. Cambio en la glucemia plasmática en ayunas (GPA): Desde el inicio hasta la semana 26
    2. Cambio de la tensión arterial sistólica (TAS) para los pacientes con una TAS basal de ≥130 mmHg.: Desde el inicio hasta la semana 12
    3. Cambio de la tensión arterial sistólica TAS: Desde el inicio hasta la semana 12
    4. Cambio en el peso corporal: Desde el inicio hasta la semana 26
    5. Cambio porcentual del cociente albúmina/creatinina (CAC): Desde el inicio hasta la semana 26
    6. Pacientes con HbA1c inferior a 6.5%: semana 26
    7. Pacientes con HbA1c inferior a 7.0%: semana 26
    8. Pacientes con acontecimientos adversos: semana 26
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned12
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA64
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Brazil
    Canada
    Colombia
    Germany
    Hungary
    Israel
    Italy
    Mexico
    Poland
    Romania
    Russian Federation
    South Africa
    Spain
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Subject Last Visist (LSLV)
    Última visita del último paciente (LPLV)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 900
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 900
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state126
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 654
    F.4.2.2In the whole clinical trial 1800
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-09-01
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-08-29
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-10-25
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 01:15:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA